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Background: RASSF1A and RASSF1C are two major isoforms encoded by the Ras association domain family 1
(RASSF1) gene through alternative promoter selection and mRNA splicing. RASSF1A is a well established tumor
suppressor gene. Unlike RASSF1A, RASSF1C appears to have growth promoting actions in lung cancer. In this
article, we report on the identification of novel RASSF1C target genes in non small cell lung cancer (NSCLC).
Methods: Over-expression and siRNA techniques were used to alter RASSF1C expression in human lung cancer
cells, and Affymetrix-microarray study was conducted using NCI-H1299 cells over-expressing RASSF1C to identify
RASSF1C target genes.
Results: The microarray study intriguingly shows that RASSF1C modulates the expression of a number of genes
that are involved in cancer development, cell growth and proliferation, cell death, and cell cycle. We have validated
the expression of some target genes using qRT-PCR. We demonstrate that RASSF1C over-expression increases, and
silencing of RASSF1C decreases, the expression of PIWIL1 gene in NSCLC cells using qRT-PCR, immunostaining, and
Western blot analysis. We also show that RASSF1C over-expression induces phosphorylation of ERK1/2 in lung
cancer cells, and inhibition of the MEK-ERK1/2 pathway suppresses the expression of PIWIL1 gene expression,
suggesting that RASSF1C may exert its activities on some target genes such as PIWIL1 through the activation of the
MEK-ERK1/2 pathway. Also, PIWIL1 expression is elevated in lung cancer cell lines compared to normal lung
epithelial cells.
Conclusions: Taken together, our findings provide significant data to propose a model for investigating the role of
RASSF1C/PIWIL1 proteins in initiation and progression of lung cancer.
Keywords: RASSF1C, PIWIL1, Gene expression, RASSF1C target genes, ERK1/2Background
Lung cancer is the leading cancer killer of both men and
women in the United States [1]. Tumor suppressors and
growth promoters play a vital role in lung cancer growth
and progression. One such tumor suppressor is
RASSF1A, which is inactivated in 80–100% of lung can-
cer cell lines and tumors [2-5]. In addition to human
tumor studies, evidence from in vitro over-expression
and knockout mouse studies demonstrate clearly that
RASSF1A is a tumor suppressor [2,6-11].* Correspondence: yousef.amaar@va.gov
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reproduction in any medium, provided the orRASSF1C is the other major isoform encoded by the
RASSF1 gene and it is expressed in the majority of
human solid tumors. Some reports suggested that
RASSF1C may function as a tumor suppressor in ovar-
ian, prostate, renal cancer cells [10-13]. In contrast, we
have recently demonstrated that RASSF1C promotes
breast and lung cancer cell proliferation [14,15]. Over-
expression of RASSF1C led to increased proliferation of
the non small cell lung cancer (NSCLC) cell line NCI-
H1299, while silencing of RASSF1C expression led to
decreased cell proliferation [14]. Consistent with our
findings, others have shown that RASSF1C, but not
RASSF1A, over-expression in the human lung cancer
cell line A549 results in significant accumulation of the
β-catenin oncogene, a key player in the Wnt signalingLtd .This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and cell proliferation [16]. Previously, we have shown
that RASSF1C is a binding partner of insulin-like growth
factor binding protein 5 (IGFBP-5), which is a member
of the IGF binding protein family that has been shown
to be critically important in lung cancer progression
[17].
There is growing evidence that RASSF1C and
RASSF1A have important and distinct roles in cancer
cell proliferation. However, it is certainly possible that
the interplay of these two molecules may be critical to
determining the eventual growth and progression char-
acteristics of lung cancers. In order to better define the
functions of RASSF1C, we used microarray expression
analysis to investigate the impact of RASSF1C on gene
regulation. We hypothesized that over-expression of
RASSF1C might either down-regulate the expression of
cell growth inhibiting/pro-apoptotic genes or up-regu-
late the expression of cell growth promoting/anti-apop-
totic genes. In this article, we report on RASSF1C
modulation of PIWIL1 gene expression in the NSCLC
cells.Methods
Cell culture
The human lung cancer cell lines A549, and NCI-
H1299, and the normal lung epithelial cell line CRL-
9482, were all obtained from American Type Culture
Collection (Manassas, VA). Cell culture was carried out
as recommended by ATCC.Construction of a tet-inducible expression system that
expresses RASSF1C
In order to over-express RASSF1C cDNA in human lung
cancer cells in a regulated fashion, we chose to use a
doxycycline (dox)-inducible Murine Leukemia Virus
based retroviral vector to express RASSF1C that was
developed at our institution as previously described
[14,18].
NCI-H1299 and A549 lung cancer cells were seeded at
1 × 105 cells/well in 6-well plates. After 24 hr of incuba-
tion, the cells were transduced with the MLV-based vec-
tors rtTA-GYT (vector without transgene, designated
“backbone”), rtTA-GYT-GFP and rtTA-GYT-HA-
RASSF1C with different MOI in 6-well plates, using 2 or
3 serial infection cycles as described [17]. After 1–4 days,
cells were treated with up to 1 × 10−6 M doxycycline
(dox) for 48 hr. Transgene expression was assessed by
Western blot analysis using anti-HA antibody. Using
cells transduced with the rtTA-GYT-GFP vector, we
demonstrated that a 10 fold induction of GFP expression
can be achieved with a dox concentration of 1ug/ml
(data not shown).RNA isolation and RT-PCR analysis
Total RNA from human lung cancer cell lines was iso-
lated from confluent cultures using the Absolutely RNA
Microprep Kit (Stratagene, La Jolla, CA). 1 μg of total
RNA was used in reverse transcriptase (RT) reactions
using the superscript kit (Qiagen, Germantown, MD)
and the RT reactions were subsequently used to set up
real-time PCR reactions using1 μl of RT as a template.
The real-time PCR reactions were set up using Syber
green PCR master mix (BioRad, Hercules, CA) and the
PCR reactions were run using the Opticon 2 PCR ma-
chine (BioRad). The PCR reactions were run using the
following protocol: 1. incubate at 95°C for 10 min, 2. in-
cubate at 95°C for 15 sec, 3. incubate for 30 sec, 4. go to
line 2 for 39 more cycles, 8. melting curve from 60°C to
95°C, read every 1.0°C, 9. incubate at 10°C forever. The
RT-PCR reactions were carried out in triplicate and the
fold change was calculated using the 2T
−ΔΔC method [19].
Cyclophyllin was used as a loading control.Western blot analysis
Western blot analysis was carried out using standard
procedures with detection on the OdysseyW Infrared
System (LI-COR Biosciences, Lincoln, NE). Rabbit poly-
clonal anti-PIWIL1 (ab12337 Abcam, Cambridge, MA),
mouse monoclonal anti-HA (Mon HA.11(16B12) Cov-
ance, Berkeley, CA), mouse monoclonal p-ERK (E-4) (
sc-7383, Santa Cruz, Biotechnology, CA), mouse anti-
panERK (Cat. 610123, BD Transduction Laboratory),
rabbit polyclonal RASSF1C antibody (gift from Dr. Geof-
frey Clark, JG Brown Cancer Center, University of Louis-
ville, KY), and goat anti-mouse and donkey anti-rabbit
fluorescently labeled secondary antibodies (IRDye@680
926–32220, LI-COR Biosciences) were used.Microarray analysis
Hybridization of 12 μg of labeled cRNA to an Affymetrix
U133 plus 2.0 chip was carried out in triplicate and data
analyses were carried out at the UCLA Microarray core
facility, Department of Pathology [14]. The control sam-
ple is RNA from NCI-H1299 cells stably transduced with
MLV-backbone (NCI-BB) and the experimental sample
is RNA from NCI-H1299 cells stably transduced with
MLV-RASSF1C (NCI-1C). Prior to RNA isolation, NCI-
BB and NCI-1C cells were treated with 1 μg/ml doxycyc-
line for 48 hr. Data analysis was performed using dChip
[20]. Thresholds for selecting significant genes were set
at a relative difference>= 1.5-fold (or/and 2-fold), abso-
lute signal difference>= 50, and p< 0.05. Genes that
met all three criteria were considered as significant
changes. Comparison results with False Discovery Rate
(FDR)< 5% was considered as a valid analysis.
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genes
Primers used for validation:
CREG forward primer: 5
GTGCCCTATTTCTACCTGAGCC 3
CREG reverse primer 5
AGCATTATGTGAACACAAAGGGG 3
EGR1 forward primer: 5
ATGAAGGAACCCTGTTTCCGT 3
EGR1 reverse primer 5
ATGATGGAGTAGATGGTGGG 3
PIWIL1 forward primer 5
GCAAAAGGTCACAGCAGACA 3
PIWIL1 reverse primer 5
CCTCCCATCTTGCAGTTCAT 3
PTGS2 forward primer 5
ATCACAGGCTTCCATTGACC 3
PTGS2 reverse primer 5
CAGGATACAGCTCCACAGCA 3
Cyclophillin forward primer 5
GCATACAGGTCCTGGCATCT 3
Cyclophillin reverse primer 5
TCTTGCTGGTCTTGCCATTC 3
Immunostaining
NCI-H1299 lung cancer cell lines stably transduced with
either MLV-back bone or MLV-HA-RASSF1C were
immunostained for the PIWIL1 protein. Cells were fixed
with methanol for 10 min and washed 3 times with PBS.
Cells were then incubated with rabbit polyclonal Anti-
PIWIL1 (ab12337 Abcam, Cambridge, MA) at 1/1000
dilution for 2 hr. Cells were washed 3 times with PBS
and incubated with Alexa Fluor 488 antibody (goat anti-
mouse IgG, Invitrogen, Carlsbad, CA) at 1/1000 dilution
for 1 hr. Cells were analyzed using a fluorescent micro-
scope with the appropriate filters.
Silencing of RASSF1C expression in lung cancer cells
Lung cancer cells (NCI-H1299) were plated at 5000/well
in 96–well plates 24 hr before infection and cells were
infected with MissionW Non-Target shRNA Control













Figure 1 Western blot analysis of normal lung epithelial cells (CRL-94
transduced with MLV-backbone (BB) or MLV-HA-RASSF1C (1C) treated
detected a HA-RASSF1C fusion protein of the expected size.Lentiviral shRNA Transduction Particles (NMID:
NM_007182) for silencing RASSF1C (Sigma, St. Louis,
MO) as previously described [14]. The NCI-H1299 lung
cancer cells used in this study do express RASSF1C but
not RASSF1A. Knockdown validation of RASSF1C ex-
pression was assessed by Western blot and qRT-PCR
using RASSF1C antibody and RASSF1C specific primers,
respectively.
Treatment of cells with the MEK/ERK inhibitor, CI-1040
Lung cancer cells were treated with 1 μM CI-1040
(Sigma) for 18 hr, then cells were collected for total
RNA and protein lysate preparations for RT-PCR and
Western blot analyses, respectively.
Results
Establishment of inducible stable NSCLC and normal lung
epithelial cell lines
NSCLC cell lines (NCI-H1299 and A549) and normal
lung epithelial cells (CRL-9482) were infected with retro-
viral vectors to create stable cell lines that inducibly
over-express the gene of interest in the presence of
doxycycline. Figure 1 shows that these cell lines stably
over-express RASSF1C after treatment with doxycycline.
Identification of novel RASSF1C target genes in NSCLC
cells
We have previously demonstrated that inhibition of
RASSF1C expression decreases, and over-expression of
RASSF1C increases, breast and lung cancer cell prolif-
eration [14,15]. This suggests that RASSF1C may have
an opposite and distinct function from that of RASSF1A
in lung cancer. The observed increase in cell prolifera-
tion in NCI-H1299 cells over-expressing RASSF1C pre-
dicted that over-expression of RASSF1C might either
down-regulate the expression of cell growth inhibiting/
pro-apoptotic genes or up-regulate the expression of cell
growth promoting/anti-apoptotic genes. To answer this
question, Affymetrix-microarray analysis was performed
using NCI-H1299 cells over-expressing RASSF1C to
identify RASSF1C target genes as outlined under Materi-










82) and lung cancer cells (NCI-H1299 and A549) stably
with 1 μg/ml doxycycline for 48 hrs. The anti-HA tag antibody
Table 1 List of selected novel RASSF1C target genes identified in NSCLC (NCI-H1299) cells
Cell Cycle and Growth
Gene Gene Description Fold change
BHLHB2 basic helix-loop-helix domain containing, class B, 2 3.06
CAV1 caveolin 1, caveolae protien, 22 kDa 2.9
CLU clusterin 3.66
CREG1 cellular repressor of E1A-stimulated genes 1 2.06
EGFR epidermal growth factor receptor 2.52
EGR1 early growth responds 1 2.35
FGF2 fibroblast growth factor 2 (basic) 2.19
GDF15 growth differentiation factor 15 2.83
HBEGF herapin-binding EGF-like growth factor 2
KLF4 Kruppel-like factor 4 (gut) 2.36
LIF leukemia inhibitory factor (cholinergic differentiation factor) 2.14
MDK midkine (neurite growth-promoting factor 2) 2.51
PLK2 polo-like kinase 2 (Drosophila) 5.79
DAL-1 Differentially expressed in adenocarcinoma of the lung-1 (DAL-1) -3.32
Cell proliferation
Gene Gene Description Fold change
ABCB ATP-binding cassette, sub-family B (MDR/TAP), member 1 2.12
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 8.07
CAV2 caveolin 2 2.05
COL4A1 collagen, type IV, alpha 1 2.96
COL4A2 collagen, type IV, alpha 2 2.92
CRABP2 cellular retinoic acid binding protein 2 2.18
CRIP2 cysteine-rich protein 2 2.23
EFNB2 ephrin-B2 −2.78
GSN gelsolin (amyloidosis, Finnish type) 2.51
KISS1 KiSS metastasis-suppressor −2.97
PIWIL1 piwi-like 1 (Drosophila) 6.87
PLK2 polo-like kinase 2 (Drosophila) 5.79
RASGEF1A RasGEF domain family, member 1A 3
Cell death
Gene Gene Description Fold change
AMIGO2 adhesion molecule with lg-like domain 2 4.16
CARD8 caspase recruitment domain family, member 8 −2.2
CASP4 caspase 4 −1.6
HBEGF heparin-binding EGF-like growth factor 2
DKK1 dickkopf homolog 1 (Xenopus laevis) 2.62
KLF4 Kruppel-like factor 4 (gut) 2.36
KLF10 Kruppel-like factor 10 2.65
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many genes that are involved in cancer development,
up-regulating genes involved in cell growth and prolif-
eration, and down-regulating genes involved in cell
death (Table 1), suggesting a potential cell growth/prolif-
eration promoting role for RASSF1C in lung cancer
cells. The microarray data is consistent with ourprevious findings that over-expression of RASSF1C
resulted in a statistically significant increase in lung can-
cer cell proliferation [15].
We then confirmed the modulation of selected
RASSF1C target genes (CREG1, EGR1, PIWIL1, and
PTGS) of interest to us using qRT-PCR (Table 2). We
also confirmed that silencing the endogenous expression
Table 2 (A) Selected RASSF1C target genes validated in
the NCI-H1299 lung cancer cell line over-expression
RASSF1C using RT-PCR. (B) Silencing of endogenous
RASSF1C expression had an opposite effect on the
expression of RASSF1C target genes
A B
Gene Fold change SD Gene Fold change SD
RASSF1C 20 0.05 RASSF1C −5 0.05
CREG 2.1 0.5 CREG −2 0.3
EGR1 1.9 0.6 EGR1 −4 0.03
PIWIL1 5.2 0.2 PIWIL1 −2.3 0.04
PTGS −2.2 0.15 PTGS 1.4 0.11
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the down-regulation of CREG1, EGR1, and PIWIL1 gene
expression, and up-regulated the expression of PTGS2
gene (Table 2).RASSF1C modulates the expression of a stem cell renewal
gene, PIWIL1
PIWIL1 is a stem cell renewal gene that has been impli-
cated in promoting cancer cell growth in a number of
different types of cancer [21-24]. However, nothing is
known about the role of PIWIL1 in lung cancer cells,
making this an interesting gene for further study. We
investigated the expression levels of PIWIL1 in lung can-
cer cell lines and found the PIWIL1 expression is indeed
elevated in lung cancer cell lines compared to normal
lung epithelial cells (Figure 2). We then further validated
the up-regulation of PIWIL1 gene expression (Table 2)
in lung cancer cells over-expressing RASSF1C using
immunostaining and Western blot analysis (Figures 3
and 4B and C). We also found that over-expression of
RASSF1C in primary lung epithelial cells slightly up-
regulates the expression of PIWIL1 gene expression























Figure 2 PIWIL1 mRNA expression in the normal lung epithelial cell li
was investigated by RT-PCR analysis. The RT-PCR analysis shows that th
H1299 compared to that in CRL-9482. The RT-PCR analysis was carried outendogenous RASSF1C expression down-regulates
PIWIL1 gene expression both at the mRNA and protein
levels (Table 2 and Figure 5) suggesting that PIWIL1
gene is an authentic target of RASSF1C.
RASSF1C may activate the MEK-ERK1/2 pathway
In order to identify the pathway(s) that may be activated
by RASSF1C in lung cancer, we looked for phosphoryl-
ation of ERK1/2, AKT and PI3K. Lung cancer cells over-
expressing RASSF1C exhibited increased levels of phos-
phorylated ERK1/2 compared to control cells (Figure 6),
suggesting that RASSF1C may exert its activities on tar-
get genes in part through the activation of the MEK-
ERK1/2 pathway. To further investigate if RASSF1C
actions are mediated by the MEK-ERK1/2 pathway, we
treated the cells with the MEK-ERK inhibitor CI-1040
and interestingly found that reduction of the ERK1/2
phosphorylation resulted in the down-regulation of
PIWIL1 mRNA levels (Figure 7) in lung cancer cells. To-
gether our findings suggest that RASSF1C actions may
be mediated in part by the MEK-ERK pathway.
Discussion
Previous work in our laboratory has demonstrated that
RASSF1C may function to regulate cell proliferation and
apoptosis [14,15,17]. We have accumulated substantial
evidence suggesting that RASSF1C may promote lung
cancer cell growth. Previously, we showed that RASSF1C
over-expression increases cell proliferation and siRNA-
mediated knockdown of endogenous RASSF1C expres-
sion decreases lung cancer cell proliferation, respectively
[15]. To begin to address the mechanisms for the effect
of RASSF1C on lung cellular growth, we carried out a
microarray study to identify novel RASSF1C target
genes. The microarray study showed that over-expres-
sion of RASSF1C stimulates expression of genes that are
associated with cell growth and proliferation and down549 NCI-H1299
*
*
ne (CRL-9482) and in two NSCLC cell lines (A549 and NCI-H1299)
e PIWIL1 mRNA levels are significantly higher in the A549 and NCI-
using the 2(−Delta Delta C (T)) Method [19].
A B
Figure 3 Immunostaining of PIWIL1 protein in NCI-H1299 lung cancer cell lines stably transduced with either MLV-backbone (NCI-
H1299-BB, A) or MLV-HA-RASSF1C (NCI-H1299-1C, B). Cells were immuno-stained using PIWIL1 antibody as described in the Methods section.
The PIWIL1 protein staining is more pronounced in NCI-H1299-1C over-expressing RASSF1C compared to NCI-1299-BB (control) cells clearly
demonstrating that RASSF1C over-expression up-regulates PIWIL1 gene expression.
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some of these target genes have previously been shown
to be involved in modulating NSCLC growth and pro-
gression. These include the up-regulation of growth pro-
moting genes such as aldehyde dehydrogenase 1A1
(ALDH1A1) [25] and caveolin-1 (CAV1) [26], and
down-regulation of growth suppressing genes like the
tumor suppressor 4.1B/differentially expressed in adeno-
carcinoma of the lung-1 (DAL-1) [27]. In addition, ex-
pression of Kruppel-like factor 4 (KLF4) [28], Ras guanyl
nucleotide exchange factor 1A (RASGEF1A) [29], and
polo-like kinase 2 (PLK2) [30] have been reported to ex-
hibit anti-apoptotic and growth-promoting activity in
human cancer cells and are also up-regulated by
RASSF1C over-expression. We also found that RASSF1C
stimulates the expression of other interesting genes such
as the stem cell self-renewal gene Piwi-like protein 1
(PIWIL1) [21], and the ABC drug transporter ABCB1
(also known as MDR1) [31]. We have confirmed expres-
sion of selected RASSF1C target genes of interest using




















Figure 4 Western blot analysis of lung primary epithelial cells CRL-94
cells stably transduced with MLV-backbone (CRL9482-BB, A549-BB, an
NCI-1C) treated with 1 μg/ml doxycycline for 24 hr. Anti-PIWIL1 antibo
H1299 and cells over-expressing RASSF1C confirming up-regulation of PIWcells with knocked-down expression of RASSF1C
(Table 2). It should be noted that RASSF1C over-expres-
sion had no effect on known RASSF1A gene targets that
have been identified in NSCLC cell line A549 and naso-
pharyngeal carcinoma cell line C666-1 over-expressing
RASSF1A [5,32]. This further supports the hypothesis
that RASSF1A and RASSF1C have distinct antagonistic
functions.
We then further focused on validating the modulation
of PIWIL1 gene expression in lung cancer cells over-
expressing RASSF1C using immunostaining and West-
ern blot analyses (Figures 3 and 4), we also found that si-
lencing of RASSF1C resulted in reduction of PIWIL1
expression (Table 2 and Figure 5). PIWIL1 protein over-
expression has been detected in many tumor types (tes-
ticular seminomas, breast, endometrial, gastrointestinal,
ovarian, prostate, and soft-tissue sarcoma), but not in
normal tissue [21-24]. In this study we also found that
PIWIL1 gene expression is significantly elevated in lung
cancer cell lines compared to normal lung epithelial cells
















82 (A), A549 (B) lung cancer cells, and NCI-H1299 (C) lung cancer
d NCI-BB) and (MLV-HA-RASSF1C: CRL9482-1C, A549-1C, and
dy detected higher levels of PIWIL1 protein in CRL-9482, A549, NCI-




























Figure 5 (A) Western blot analysis of NCI-H1299 lung cancer cells infected with MissionW Lentiviral-shRNA-control particles (NCI-non-
target siRNA) and MissionW Lentiviral-shRNA-RASSF1C (NCI-RASSF1C siRNA) to silence endogenous RASSF1C expression. (B) Anti-PIWIL1
antibody detected less PIWIL1 protein signals in cells with Knocked-down RASSF1C expression compared to control.
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chosen PIWIL1 for further investigation for reasons that
it may have important functions in cancer stem cell initi-
ation, maintenance, or progression as nothing is known
about the function of this interesting gene in lung can-
cer. We are interested in pursuing studies to determine
the mechanism(s) through which RASSF1C modulates
PIWIL1 gene expression and its impact on lung cancer
cell growth. In this regard, we found that RASSF1C
over-expression induces phosphorylation of ERK1/2 in
lung cancer cells (Figure 6), raising the hypothesis that
RASSF1C could exert its activities on some target genes
such as PIWIL1 through the activation of the MEK-
ERK1/2 pathway which controls a wide variety of target
genes. To further investigate this hypothesis, we inhib-
ited the MEK-ERK pathway using CI-1040, a known in-
hibitor of the MEK-ERK pathway. We found that
inhibition of the MEK-ERK pathway led to the down-












Figure 6 ERK1/2 activation was assessed in NCI-H1299 and A549 lung
recognize phosphospecific or total ERK1 and ERK2. The level of phosph
1C significantly higher compared to control cells (NCI-BB and A549-BB).is the first to propose a potential link between RASSF1C
actions and the MEK-ERK1/2 pathway.
Taken together, our findings provide significant data to
propose a model for investigating the role of RASSF1C/
MEK-ERK1/2 pathway in initiation and progression of
lung cancer cells in vitro and in vivo (Figure 8). We have
shown that RASSF1C modulates PIWIL1 gene expres-
sion, potentially through the activation of MEK-ERK1/2
pathway. This leads us to the hypothesis that RASSF1C
may play a role in early lung cancer initiation and pro-
gression through the activation of ERK1/2 and deregula-
tion of PIWIL1 gene expression in lung cancer stem
cells. PIWI-like proteins belong to the argonaute family
which is involved in stem cell self-renewal. The PIWI-
like proteins do interact with small RNA molecules
known as PIWI-interacting RNAs (piRNAs) to form
complexes that regulate transcriptional and translational
repression leading to inhibition of apoptosis and stimu-












cancer cells over-expressing RASSF1C using antibodies that
orylated ERK1/2 in cells over-expressing RASSF1C (NCI-1C and A549-
Figure 7 (A) Treatment of NCI-H1299 with the MEK-ERK1/2 pathway inhibitor CI1040 resulted in down-regulating PIWIL1 mRNA levels.
(B) Treatment of NCI-H1299 with CI1040 reduces pERK1/2 levels.
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the self-renewal of stem cells are actually deregulated in
cancer stem cells causing uncontrolled expansion of self-
renewing cancer cells and tumor formation [33,34].
Our findings are also supported by results from other
groups, which have shown that unopposed RASSF1C ex-
pression leads to accumulation of the oncogene β-cate-
nin, which is an important part of the Wnt signaling
pathway [16]. More intriguingly, elevated levels
RASSF1C mRNA are found in all types of lung carcin-
oma and pancreatic tumors compared to correspondingFigure 8 Hypothetical Model of RASSF1C action in lung cancer cells:
pathway which controls a wide variety of genes that promote cell div
which RASSF1C may impact PIWIL1 expression. Since PIWIL1 is widely over
important functions in cancer initiation, maintenance, or progression. PIWI-
form complexes that regulate transcriptional and translational repression le
proliferation. Up-regulation of PIWIL1gene expression by RASSF1C is a nove
early lung cancer development and progression.normal tissue samples further supporting our hypothesis
that RASSF1C plays a role in lung cancer development
and progression [35,36].
Conclusion
Identifying RASSF1C target genes related to stem cell
self-renewal and survival that include PIWIL1,
ALDH1A1, and ABCB1, and linking the activities of
RASSF1C to the MEK-ERK pathway are excitingly novel
findings that would allow us to pursue future studies to
investigate the impact of RASSF1C and the underlingwe hypothesize that RASSF1C in part activates the MEK-ERK1/2
ision and proliferation. The model proposes a mechanism through
-expressed in tumors compared to normal tissue, it may have
like proteins interact with PIWI-interacting RNA molecules (piRNAs) to
ading to inhibition of apoptosis and stimulation of cell division and
l and exciting discovery, suggesting a potential role for RASSF1C in
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http://www.biomedcentral.com/1756-0500/5/239pathway(s) associated on lung cancer development and
progression.
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